CRISPR Therapeutics AG - Common Shares (CRSP)
$44.40
0.11 (0.25%)
CRSP Stock Quote Delayed 30 Minutes
3 Reasons to Go Long Crispr Therapeutics
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
3.50B
PE Ratio
-10.21
EPS
-4.35
Volume (Avg. Vol.)
1.24M
Day's Range
$43.97 - $46.00
52-Week Range
$36.52 - $90.62
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and CRISPR Therapeutics AG - Common Shares News
Consider Adding New Positions in U.S. Cannabis Stocks
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR Has the Potential to Cure Cancer and Make You Triple-Digit Gains
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
Why CRSP Stock Has Added Layers of Risk
Even by biotech standards, CRSP stock is volatile and prone to snap reactions -- but the potential rewards are huge.
Gene Editing is a Major Technology to Watch
Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.
A Single Study Is No Reason to Sell Crispr Stock
Crispr stock is down 7% on the release of a new study. But the headline is not nearly as scary as it sounds.
After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall
Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.
